Travere Therapeutics (NASDAQ:TVTX) CFO Sells $13,624.50 in Stock

Key Points

• CFO Christopher Cline sold 310 shares at an average price of $43.95 for $13,624.50 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, reducing his stake by 0.26% to 118,658 shares.
• Travere posted an EPS beat for Q1 ( $0.05 vs. $-0.24 est.) with revenue up 55.6% year‑over‑year, and analysts remain mostly positive—consensus is a Moderate Buy with an average target of $47.83 amid several price‑target upgrades.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 310 shares of the firm's stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $13,624.50. Following the completion of the sale, the chief financial officer owned 118,658 shares of the company's stock, valued at $5,215,019.10. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

NASDAQ:TVTX traded down $0.10 during mid-day trading on Wednesday, hitting $44.70. The stock had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. The company's 50 day simple moving average is $32.59 and its 200 day simple moving average is $32.83. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same period last year, the business posted ($0.47) EPS. Travere Therapeutics's revenue was up 55.6% on a year-over-year basis. On average, equities research analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Travere Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock valued at $158,059,000 after buying an additional 619,085 shares in the last quarter. State Street Corp raised its position in shares of Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after buying an additional 1,538,827 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Travere Therapeutics by 12.7% in the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock valued at $163,469,000 after buying an additional 483,565 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock valued at $41,203,000 after buying an additional 599,102 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Travere Therapeutics by 28.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock valued at $85,849,000 after buying an additional 494,665 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TVTX shares. JPMorgan Chase & Co. reduced their price objective on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a report on Wednesday, March 25th. Guggenheim lifted their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, April 24th. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a report on Tuesday, April 14th. Finally, Piper Sandler upgraded Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price objective on the stock in a research report on Tuesday, April 14th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.